| Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. | |
| | |
MedLine Citation:
|
PMID: 8201477 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129G, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-linked immunosorbent assay titers to pertussis toxin, filamentous hemagglutinin, and pertactin, as well as the pertussis toxin-neutralizing titer measured by the Chinese hamster ovary cell assay, were significantly higher after the acellular vaccine was given. Both vaccines induced adequate levels of anti-diphtheria and anti-tetanus antibodies. We conclude that the recombinant acellular pertussis vaccine produces fewer reactions than the whole-cell vaccine and provides a high antibody response against the antigens of Bordetella pertussis involved in bacterial adhesion and systemic toxic effects. |
| | |
Authors:
|
A Podda; E C De Luca; B Contu; R Furlan; A Maida; A Moiraghi; D Stramare; L Titone; F Uxa; F Di Pisa; S Peppoloni |
Related Documents
:
|
3537247 - Neurologic complications of immunizations. 19007547 - The re-emergence of pertussis: implications for diagnosis and surveillance. 17991417 - Incidence trends in pertussis in the autonomous region of madrid, spain: 1982-2005. 9635377 - Disputed claims for pertussis vaccine injuries under the national vaccine injury compen... 1512717 - Immunotherapeutic modification of escherichia coli peritonitis and bacteremia by tinosp... 3537247 - Neurologic complications of immunizations. |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Journal of pediatrics Volume: 124 ISSN: 0022-3476 ISO Abbreviation: J. Pediatr. Publication Date: 1994 Jun |
Date Detail:
|
Created Date: 1994-07-06 Completed Date: 1994-07-06 Revised Date: 2009-12-01 |
Medline Journal Info:
|
Nlm Unique ID: 0375410 Medline TA: J Pediatr Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 921-6 Citation Subset: AIM; IM |
Affiliation:
|
Biocine R & D Vaccines, Siena, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Bacterial
/
biosynthesis Bordetella pertussis / immunology* Diphtheria-Tetanus-Pertussis Vaccine* / adverse effects, immunology Double-Blind Method Female Humans Infant Male Pertussis Vaccine* / adverse effects, immunology Prospective Studies Vaccines, Synthetic / adverse effects, immunology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Bacterial; 0/Diphtheria-Tetanus-Pertussis Vaccine; 0/Pertussis Vaccine; 0/Vaccines, Synthetic |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Diagnostic value of anti-neutrophil cytoplasmic and anti-endothelial cell antibodies in early Kawasa...
Next Document: A possible genetic defect in 25-hydroxylation as a cause of rickets.